Ken Shain, MD, PhD
Ken Shain, MD, PhD
Specialty: Internal Medicine
Program: Malignant Hematology
Research Program: Molecular Medicine Program
-
Overview
To date, Dr. Shain has been actively participating in translation research in multiple myeloma and other hematologic malignancies, with 40 publications as well as a number of book chapters. Clinically, Dr. Shain is/has been the principal investigator and co-investigator of a number of clinical trials in multiple myeloma. His translational research has focused on the mechanisms by which components of the bone marrow microenvironment influence myeloma biology, survival, and drug response. He is currently collaborating with a wide range of Moffitt and non-Moffitt researchers, mathematicians, clinicians and other groups to carry out his research goals.
Associations
- Malignant Hematology
- Tumor Microenvironment and Metastasis
- Pentecost Family Myeloma Research Center
- Systems Medicine Working Group
- Molecular Medicine Program
- Experimental Therapeutics Program
Education & Training
Graduate:
- University of South Florida, PhD - Biochemistry & Molecular Biology
Board Certification:
- Internal Medicine - Medical Oncology
Fellowship:
- University of South Florida College of Medicine, Moffitt Cancer Center - Hematology/Oncology
Residency:
- University of South Florida College of Medicine - Internal Medicine
Medical School:
- University of South Florida College of Medicine - MD
-
Research Interest
This research goal and desire to bring personalized therapy to the forefront of myeloma therapy involves several projects – (1) Personalized care of multiple myeloma: A) EMMA (evolutionary mathematical myeloma advisor) - a novel collaboration with critical alliance with our integrated mathematical oncology department (Dr. Robert Gatenby, Dr. Robert Gilles and Dr. Ariosto Silva among others) characterizing aspects of the evolution of drug response. This collaboration has led the development of a novel mathematically-based model to predict patient response to therapy; thus, facilitating potential for the design of patient-specific/optimized therapeutic strategies that could extend survival in patients. B) GEP (gene expression profiling) - under a sponsored research agreement with Signal Genetics we will develop GEP signatures to better define risk of progression for antecedent conditions and to better inform key patient management decisions in multiple myeloma. (2) Targeting mediators of plasma cell development: Using three different mouse models we have identified a heretofore uncharacterized role of the histone deacetylase (HDAC), HDAC11, in plasma cell differentiation and biology. Our preliminary data indicate that HDAC11, the most recently identified HDAC, is critical for B cell development, more specifically plasma cell differentiation in vivo. Ongoing research will hopefully lead to the development of targeted therapeutics and clinical trials in myeloma patients. (3) Microenvironment-modulated synthetic lethality: Microenvironmental determinants alter tumor drug response; thereby, conferring myeloma survival and drug resistance. To this end, major questions remain: A) Can we identify key environmental determinants facilitating this survival phenotype to combat EMDR, MRD (minimal residual disease), and relapse? B) Can we identify drug targets that exhibit a TME-induced “synthetic lethality” (e.g. drugs with increased activity within the context of the TME)? We have recently identified PYK2/FAK2 as a target meeting this criteria and are working on translating this into clinical trials in collaboration with Verastem.
-
Participating Trials
Clinical Trial 21219
Predicting Progression of Developing Myeloma in a High-Risk Screened Population
Condition: Malignant Hematology
Status: OpenClinical Trial 21551
A Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)
Condition: Malignant Hematology
Intervention: Bortezomib (); CC-5013 (Lenalidomide); Daratumumab (Darzalex); Dexamethasone (); Lenalidomide (Revlimid); PS-341 (Bortezomib); Velcade (Bortezomib); carfilzomib (Kyprolis)
Status: OpenClinical Trial 22534
Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (TaIP), Talquetamab in Combination with Teclistamab (TaITec), and Investigators Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received an AntiCD38 Antibody and Lenalidomide (MonumenTAL-6)
Condition: Malignant Hematology
Intervention: Bortezomib (); CC-4047 (Pomalidomide); Dexamethasone (); Elotuzumab (); PS-341 (Bortezomib); Pomalidomide (); Talquetamab (); Teclistamab (); Velcade (Bortezomib)
Status: Open (affiliates only)If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775. -
Publications
- Badros AZ, Foster L, Anderson LD, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2024 Sep. Pubmedid: 39331724.
- Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future Oncol. 2024 Oct.1-25. Pubmedid: 39452950.
- Shabnaz S, Nguyen TN, Williams R, Rubinstein SM, Garrett TJ, Tantawy M, Fradley MG, Alomar ME, Shain KH, Baz RC, Lenihan D, Cornell RF, Lu Q, Gong Y. Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma. Clin Transl Sci. 2024 May.17(5):e13828. Pubmedid: 38783568. Pmcid: PMC11116757.
- Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: 38123069.
- Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
- Bishop RT, Miller AK, Froid M, Nerlakanti N, Li T, Frieling JS, Nasr MM, Nyman KJ, Sudalagunta PR, Canevarolo RR, Silva AS, Shain KH, Lynch CC, Basanta D. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat Commun. 2024 Mar.15(1):2458. Pubmedid: 38503736. Pmcid: PMC10951361.
- Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 Jul.99(7):1257-1268. Pubmedid: 38622840.
- Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 Jul.14(1):107. Pubmedid: 38977707. Pmcid: PMC11231363.
- Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024 Apr.42(11):1229-1240. Pubmedid: 38194610. Pmcid: PMC11095887.
- Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 Apr.14(1):69. Pubmedid: 38649340. Pmcid: PMC11035596.
- Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
- Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct.10(10):e825-e837. Pubmedid: 37708911.
- Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clin Cancer Res. 2023 Nov.29(22):4575-4585. Pubmedid: 37735756.
- Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 Mar.29(3):174.e1-174.e10. Pubmedid: 36494017.
- Tantawy M, Yang G, Algubelli RR, DeAvila G, Rubinstein SM, Cornell RF, Fradley MG, Siegel EM, Hampton OA, Silva AS, Lenihan D, Shain KH, Baz RC, Gong Y. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. Front Cardiovasc Med. 2023 Jun.10:1181806. Pubmedid: 37408649. Pmcid: PMC10319068.
- Burger KL, Fernandez MR, Meads MB, Sudalagunta PR, Oliveira PS, Renatino Canevarolo R, Alugubelli RR, Tungsevik A, De Avila G, Silva M, Graeter AI, Dai H, Vincelette ND, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton OA, Koomen JM, Roush WR, Monastyrskyi A, Berglund AE, Silva AS, Cleveland JL, Shain KH. CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma. Cancer Res. 2023 Dec.83(23):3901-3919. Pubmedid: 37702657. Pmcid: PMC10690099.
- Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
- Kareem SS, Viswanathan N, Sahebjam S, Tran ND, Gatewood T, Tobon K, Baz R, Piña Y, Shain KH, Mokhtari S. Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma. Onco Targets Ther. 2022 Sep.15:953-962. Pubmedid: 36097632. Pmcid: PMC9464026.
- Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. Replicative Instability Drives Cancer Progression. Biomolecules. 2022 Oct.12(11). Pubmedid: 36358918. Pmcid: PMC9688014.
- Gao J, Wang MY, Ren Y, Lwin T, Li T, Yan JC, Sotomayor EM, Duckett DR, Shah BD, Shain KH, Zhao X, Tao J. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. Haematologica. 2022 May.107(5):1119-1130. Pubmedid: 34162179. Pmcid: PMC9052927.
- Song J, Zhang H, Dong N, Zhang X, Hussaini M, Jain A, Moscinski L, Shain K, Baz R, Alsina M, Nishihori T, Zhang L. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. Clin Lymphoma Myeloma Leuk. 2022 Jun.22(6):e414-e426. Pubmedid: 34998786.
- Peres LC, Colin-Leitzinger C, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton O, Alsina M, Brayer J, Blue B, Baz R, Siqueira Silva A, Nishihori T, Shain KH, Gillis N. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022 Jun.6(12):3767-3778. Pubmedid: 35500227. Pmcid: PMC9631567.
- Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Ne. 2022 Jan.20(1):8-19. Pubmedid: 34991075.
- Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
- Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Aug.22(8):e770-e776. Pubmedid: 35504808.
- Jiang Q, Sudalagunta P, Silva MC, Canevarolo RR, Zhao X, Ahmed KT, Alugubelli RR, DeAvila G, Tungesvik A, Perez L, Gatenby R, Gillies R, Baz R, Meads MB, Shain KH, Silva AS, Zhang W. CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation. Bioinformatics. 2022 Aug.38(16):4002-4010. Pubmedid: 35751591. Pmcid: PMC9991899.
- Hussaini MO, Srivastava J, Lee LW, Nishihori T, Shah BD, Alsina M, Pinilla-Ibarz J, Shain KH. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Arch Pathol Lab Med. 2022 Apr.146(4):485-493. Pubmedid: 34343238.
- Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, Li L, Sharma K, Nkwocha J, Parker R, Bui D, McCarter J, Kramer L, Purcell C, Sudalagunta P, Renatino Canevarolo R, Coelho Siqueira Silva MD, DeAvila G, Alugubelli RR, Siqueira Silva A, Kmieciak M, Ferreira-Gonzalez A, Shain KH, Grant S. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021 Oct.5(19):3776-3788. Pubmedid: 34464977. Pmcid: PMC8679669.
- Lo CH, Shay G, McGuire J, Li T, Shain K, Choi JY, Fuerst R, Roush WR, Knapinska AM, Fields GB, Lynch CC. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. Cancer Res. 2021 May.81(9):2415-2428. Pubmedid: 33526510. Pmcid: PMC8809361.
- Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Cancers (Basel). 2021 May.13(11). Pubmedid: 34071205. Pmcid: PMC8198550.
- Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 Mar.34(11):108870. Pubmedid: 33730585. Pmcid: PMC8057695.
- Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
- Wang MY, Li T, Ren Y, Shah BD, Lwin T, Gao J, Shain KH, Zhang W, Zhao X, Tao J. MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. Blood Cancer J. 2021 Jan.11(1):14. Pubmedid: 33446629. Pmcid: PMC7809345.
- Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
- Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 Jul.34(7):1866-1874. Pubmedid: 32060406. Pmcid: PMC7326699.
- Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Dec.18(12):1685-1717. Pubmedid: 33285522.
- Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes T, Orlowski RZ, Shain KH, Cowan AJ, Murphy SP, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin T, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug.136(8):936-945. Pubmedid: 32325490. Pmcid: PMC7441167.
- Sudalagunta P, Silva MC, Canevarolo RR, Alugubelli RR, DeAvila G, Tungesvik A, Perez L, Gatenby R, Gillies R, Baz R, Meads MB, Shain KH, Silva AS. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine. 2020 Apr.54:102716. Pubmedid: 32268267. Pmcid: PMC7136599.
- Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 Nov.94(11):1244-1253. Pubmedid: 31456261.
- Koomen DC, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meads MB, Nguyen T, Meke L, Eschrich SA, Shain KH, Garrett TJ, Koomen JM. Proteometabolomics of Melphalan Resistance in Multiple Myeloma. Methods Mol Biol. 2019 May.1996:273-296. Pubmedid: 31127562. Pmcid: PMC7771550.
- Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 2019 May.35(5):752-766.e9. Pubmedid: 31085176. Pmcid: PMC6945775.
- Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Brit J Haematol. 2019 Mar.184(5):735-743. Pubmedid: 30548250. Pmcid: PMC7771320.
- Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 Jan.133(4):299-305. Pubmedid: 30523119.
- Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynolds CH, Shain K, Zackon I, Stampleman L, Henrick P, Rivotto BJ, Hornburg K, Dumke H, Chuma S, Savell A, Handisides D, Kroll S, Anderson KC, Richardson PG, Ghobrial IM. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 Jan.25(2):478-486. Pubmedid: 30279233. Pmcid: PMC6335171.
- Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH. Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leuk Res. 2019 Aug.83:106172. Pubmedid: 31229804. Pmcid: PMC6871647.
- Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019 Aug.9(9):66. Pubmedid: 31420532. Pmcid: PMC6697695.
- Shah B, Zhao X, Silva AS, Shain KH, Tao J. Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All. Trends Cancer. 2018 Mar.4(3):197-206. Pubmedid: 29506670.
- Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Brit J Haematol. 2018 Jan.180(2):271-275. Pubmedid: 29048105.
- Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 Dec.128(12):5517-5530. Pubmedid: 30260324. Pmcid: PMC6264635.
- Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar.58(3):560-568. Pubmedid: 27424609. Pmcid: PMC7771364.
- Silva AS, Silva MC, Sudalagunta P, Distler AI, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt CL, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby RA, Gillies RJ, Sontag E, Meads MB, Shain K. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017 Jun.77(12):3336-3351. Pubmedid: 28400475. Pmcid: PMC7819642.
- Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan.18(1):112-121. Pubmedid: 27927582. Pmcid: PMC7771361.
- Nishihori T, Shain K. Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. Int J Genomics. 2017 Dec.2017:6934183. Pubmedid: 29250532. Pmcid: PMC5698810.
- Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 Apr.8:14920. Pubmedid: 28416797. Pmcid: PMC5399304.
- Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016 Nov.7(48):78896-78909. Pubmedid: 27806331. Pmcid: PMC5340237.
- Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May.127(21):2561-2568. Pubmedid: 26932802.
- Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. 2016 May.35(21):2723-2734. Pubmedid: 26387544. Pmcid: PMC4801703.
- Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul.5(7):1694-1701. Pubmedid: 27098006. Pmcid: PMC4944897.
- Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016 Aug.9(1):73. Pubmedid: 27557643. Pmcid: PMC4997728.
- Nishihori T, Song J, Shain KH. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep. 2016 Apr.11(2):118-126. Pubmedid: 26898557. Pmcid: PMC4819726.
- Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. 2015 Sep.34(36):4673-4682. Pubmedid: 25639873. Pmcid: PMC4688902.
- Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015 Oct.121(20):3622-3630. Pubmedid: 26149422.
- Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Nov.95(5):426-435. Pubmedid: 25600676. Pmcid: PMC4508238.
- Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods. 2015 Jun.81:41-49. Pubmedid: 25782629. Pmcid: PMC4460980.
- Silva A, Jacobson T, Meads M, Distler A, Shain K. An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells. J Vis Exp. 2015 Jul.(101):e53070. Pubmedid: 26274375. Pmcid: PMC4544963.
- Nishihori T, Komrokji R, Shain K, Anasetti C. Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant. 2015 Feb.50(2):296-297. Pubmedid: 25330222.
- Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan.89(1):62-67. Pubmedid: 24030918. Pmcid: PMC4522918.
- Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2014 Jan.74(1):56-67. Pubmedid: 24310398. Pmcid: PMC3915502.
- Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation. Bone Marrow Transplant. 2014 Jan.49(1):148-149. Pubmedid: 23933759.
- Shain KH, Tao J. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene. 2014 Aug.33(32):4107-4113. Pubmedid: 24037527. Pmcid: PMC4669099.
- Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep.48(9):1179-1184. Pubmedid: 23542223. Pmcid: PMC4500071.
- Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep.37(9):1077-1082. Pubmedid: 23809054.
- Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov.18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
- Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar.2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
- Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun.157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
- Shain K. Metastatic myeloma?. Blood. 2012 Jun.119(24):5612-5613. Pubmedid: 22700691.
- Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2011 Nov.10(11):M110.005520. Pubmedid: 21846842. Pmcid: PMC3226396.
- Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec.11(6):507-511. Pubmedid: 21813352.
- Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009 Feb.69(3):1009-1015. Pubmedid: 19155309. Pmcid: PMC2680075.
- Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009 Dec.69(24):9367-9375. Pubmedid: 19934314. Pmcid: PMC4519834.
- Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol. 2009 Dec.2(6):649-662. Pubmedid: 21082957.
- Perez L, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol. 2008 Feb.180(3):1545-1555. Pubmedid: 18209050.
- Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol. 2005 Apr.174(7):3925-3931. Pubmedid: 15778348. Pmcid: PMC2632804.
- Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004 Jan.10(1):48-54. Pubmedid: 14702634.
- Dalton W, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol. 2004 Apr.41(2 Suppl 4):1-5. Pubmedid: 15190509.
- Hazlehurst L, Enkemann S, Beam C, Argilagos R, Painter J, Shain K, Saporta S, Boulware L, Moscinski L, Alsina M, Dalton W. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003 Nov.63(22):7900-7906. Pubmedid: 14633719.
- Chen T, Yang I, Irby R, Shain K, Wang H, Quackenbush J, Coppola D, Cheng JQ, Yeatman T. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 2003.63(15):4368-4374. Pubmedid: 12907606.
- Shain K, Landowski T, Dalton W. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol. 2002 Mar.168(5):2544-2553. Pubmedid: 11859150.
- Shain K, Dalton W. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001 Nov.1(1):69-78. Pubmedid: 12467240.
- Niu G, Shain K, Huang M, Ravi R, Bedi A, Dalton W, Jove R, Yu H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001 Apr.61(8):3276-3280. Pubmedid: 11309279.
- Shain K, Landowski T, Dalton W. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000 Nov.12(6):557-563. Pubmedid: 11085455.
- Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000 May.14(5):830-840. Pubmedid: 10803514.
- Anderson K, Kyle R, Dalton W, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am Soc Hematol Educ Program. 2000 Dec.147-165. Pubmedid: 11701540.
- Shain K, Jove R, Olashaw N. Constitutive RelB activation in v-Src-transformed fibroblasts: requirement for IkappaB degradation. J Cell Biochem. 1999 May.73(2):237-247. Pubmedid: 10227387.
- Landowski T, Shain K, Oshiro M, Buyuksal I, Painter J, Dalton W. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood. 1999 Jul.94(1):265-274. Pubmedid: 10381522.
- Azizan A, Cong Y, Shain K, Tsai S, Olashaw N, Seto E. Transactivation by expression of the hepatitis B virus X protein with an inducible system. Mol Biol Rep. 1998 Nov.25(4):231-236. Pubmedid: 9870613.
-
Grants
- Title: Developing ULK3 inhibitors for the treatment of Multiple Myeloma
Sponsor: Florida Biomedical Research Program (FBRP)
PI: Lawrence, N., CO-PI: Lynch, C., CO-PI: Shain, K. - Title: The effects of Selinexor on the MM and the immune effector cells in the context of T cell engagement
Sponsor: Karyopharm Therapeutics, Inc.
PI: Shain, K., CO-PI: Silva, A.
- Title: Developing ULK3 inhibitors for the treatment of Multiple Myeloma